ACQUISITION OF THE PHARMACEUTICAL PRODUCT ANTIRETROVIRAL DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR 50 MG + 300 MG + 300 MG TABLET, FOR SUPPLY FOR A PERIOD OF TWELVE (12) MONTHS

This tender, Process LP-SM-22-2025-CENARES/ MINSA-1, is a public tender for the acquisition of a specific pharmaceutical product. The item is an antiretroviral medication combining Dolutegravir 50 mg, Lamivudine 300 mg, and Tenofovir 300 mg in tablet form. The contract aims to secure a supply of this medication for a period of twelve (12) months. The contracting entity is the CENTRO NACIONAL DE ABASTECIMIENTO DE RECURSOS ESTRATEGICOS EN SALUD (National Center for the Supply of Strategic Health Resources - CENARES), which operates under the Ministry of Health (MINSA). The purpose of this acquisition is to ensure the continuous availability of essential antiretroviral treatment for patients, likely those living with HIV/AIDS, managed by the national health system. Ensuring an adequate and timely supply of this combination therapy is critical for effective treatment adherence and management of the condition. The procurement method is a Public Tender, indicating a standard competitive bidding process to select a supplier that meets the required quality, quantity, and delivery specifications. The contracting entity is based in Lima.

This is a supplies contract in the governance and public administration sector. Located in Peru, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of PEN 22.7 million.

Published through Peru SEACE, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.